MG
CRL icon

Marex Group’s Charles River Laboratories CRL Stock Holding History

Marex Group’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$579K Buy
2,551
+1,182
+86% +$210K ﹤0.01% 651
2026
Q1 		$236K Buy
+1,369
New +$254K ﹤0.01% 853

Other funds holding CRL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Marex Group's CRL Position: Q2 2026 in Review

Marex Group increased its Charles River Laboratories (CRL) stake by 86% in Q2 2026, buying an estimated $210K and bringing the position to 2,551 shares worth $579K. The position accounts for ﹤0.01% of the portfolio, ranked #651.

Marex Group first reported a position in CRL in Q1 2026 and has held it in 2 quarters since. 570 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Marex Group held 2,551 shares of Charles River Laboratories worth $579K as of Q2 2026.
  • Marex Group bought 1,182 Charles River Laboratories shares in Q2 2026, an estimated $210K.
  • Charles River Laboratories made up ﹤0.01% of Marex Group's portfolio in Q2 2026, its #651 holding.
  • Marex Group first reported a position in Charles River Laboratories in Q1 2026 and has held it in 2 quarters since.
  • 570 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Marex Group's 13F filing for Q2 2026, filed 14 Aug 2026.